1. Home
  2. LABT vs CELZ Comparison

LABT vs CELZ Comparison

Compare LABT & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$2.05

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Logo Creative Medical Technology Holdings Inc.

CELZ

Creative Medical Technology Holdings Inc.

HOLD

Current Price

$0.71

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LABT
CELZ
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.1M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
LABT
CELZ
Price
$2.05
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1M
341.5K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.08
EPS
N/A
N/A
Revenue
N/A
$6,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.69
52 Week High
$6.85
$6.25

Technical Indicators

Market Signals
Indicator
LABT
CELZ
Relative Strength Index (RSI) 39.79 29.60
Support Level $1.85 N/A
Resistance Level $2.92 $0.93
Average True Range (ATR) 0.64 0.06
MACD -0.01 0.03
Stochastic Oscillator 7.51 4.67

Price Performance

Historical Comparison
LABT
CELZ

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About CELZ Creative Medical Technology Holdings Inc.

Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.

Share on Social Networks: